Page 4 - நோயாளிகள் அப்பால் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from நோயாளிகள் அப்பால். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In நோயாளிகள் அப்பால் Today - Breaking & Trending Today

Antengene Announces the Completion of Its Manufacturing Center in Shaoxing to Accelerate the Commercialization of Novel Anti-Cancer Therapies

Share this article
Share this article
SHANGHAI and HONG KONG, May 13, 2021 /PRNewswire/ Today, Antengene Corporation Limited ( Antengene , SEHK: 6996.HK) successfully hosted an inauguration ceremony for its manufacturing center at the Binhai Life Science and Healthcare Industrial Zone in Shaoxing. The completion of the manufacturing center paves the way for Antengene s future production of oral medicines and marks a major milestone in Antengene s transition into an innovative biopharmaceutical company with integrated capabilities in discovery, development, manufacturing, and commercialization. At this site, Antengene plans to soon initiate the manufacturing of selinexor, the company s first selective inhibitor of nuclear compound.
Ribbon-cutting Ceremony ....

Bo Shan , Yangtze Delta , China General , Jay Mei , Chua Zheng , Asia Pacific , Shaoxing Binhai New Area Administrative Council , Shanghai International Center , Antengene Corporation , Antengene Corporation Limited , Standing Committee Of Yuecheng District , Standing Committee , Yuecheng District , Deputy Director , Chief Scientific Officer , Binhai New Area , Technological Innovations , Binhai New , Fourteenth Five Year Plan , Corporation Limited , Asia Pacific Region , Patients Beyond , போ ஷான் , யாங்க்ட்ஜே டெல்டா , சீனா ஜநரல் , ஜெய் மெய் ,

Antengene Announces the IND Approval for Eltanexor in Patients with Advanced Solid Tumors in Mainland China

Antengene Announces the IND Approval for Eltanexor in Patients with Advanced Solid Tumors in Mainland China
News provided by
Share this article
Share this article
SHANGHAI and HONG KONG, May 13, 2021 /PRNewswire/ Antengene Corporation Limited ( Antengene , SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, announced that China s National Medical Products Administration (NMPA) has approved the initiation of a Phase Ib/II open-label, multicenter, dose-escalation study of eltanexor (ATG-016) in patients with advanced solid tumors (the REACH study).
This study aims to assess the safety and efficacy of eltanexor monotherapy in patients with advanced solid tumors. The Phase Ib part of the study will be carried out in patients with advanced solid tumors, including those with KRAS-mutant, p53 wild-type, human papill ....

Jay Mei , Asia Pacific , China National Medical Products Administration , Antengene Corporation , Prnewswire Antengene Corporation Limited , Antengene Corporation Limited , Corporation Limited , National Medical Products Administration , Asia Pacific Region , Patients Beyond , ஜெய் மெய் , ஆசியா பெஸிஃபிக் , நிறுவனம் வரையறுக்கப்பட்டவை , ஆசியா பெஸிஃபிக் பகுதி , நோயாளிகள் அப்பால் ,

Antengene Announces IND Approval in China for a Global Phase III Trial of Selinexor in Advanced or Recurrent Endometrial Cancer

Antengene Announces IND Approval in China for a Global Phase III Trial of Selinexor in Advanced or Recurrent Endometrial Cancer
News provided by
Share this article
Share this article
SHANGHAI and HONG KONG, May 12, 2021 /PRNewswire/ Antengene Corporation Limited ( Antengene , SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that China s National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for a Phase III clinical trial designed to evaluate the safety and efficacy of selinexor (XPOVIO®) in the treatment of advanced or recurrent endometrial cancer (the SIENDO trial). ....

United States , New Zealand , South Korea , Jay Mei , Asia Pacific , Karyopharm Therapeutics Inc , Antengene Corporation , European Commission , Drug Administration , China National Medical Products Administration , Prnewswire Antengene Corporation Limited , Antengene Corporation Limited , Connective Tissue Oncology Society , Ministry Of Food , Israeli Ministry Of Health , Child Health , National Comprehensive Cancer Network , Chinese Society Of Clinical Oncology , Corporation Limited , National Medical Products Administration , Investigational New Drug , Chinese Society , Clinical Oncology , Treatment Guidelines , North America , China Maternal ,

Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines

Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines
News provided by
Share this article
Share this article
SHANGHAI and HONG KONG, May 5, 2021 /PRNewswire/ Antengene Corporation Limited ( Antengene , SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that the Chinese Society of Clinical Oncology (CSCO), the most prominent organization in oncology in China,
added multiple selinexor regimens to its 2021 Diagnosis and Treatment Guidelines (CSCO Guidelines) for treatment of multiple myeloma and lymphoma. Three selinexor regimens recommended by the Guideline for the Diagnosis and Treatment of myeloma include: (i) selinexor plus dexamethasone; and (ii) selinexor plus dexamethasone plus bortezomib; and (iii) selinexor plus dexamethasone plus pomalidomide for t ....

Kyongsang Bukto , South Korea , New Zealand , Hong Kong , Wenming Chen , Asia Pacific , Depei Wu , Chao Yang Hospital Of The Capital Medical University , Karyopharm Therapeutics Inc , Antengene Corporation , European Commission , Drug Administration , Chinese Medical Education Association Committee On Hematology , Antengene Corporation Limited , Connective Tissue Oncology Society , Ministry Of Food , First Affiliated Hospital Of Soochow University , Israeli Ministry Of Health , National Comprehensive Cancer Network , Chinese Society , Chinese Medical Association , First Affiliated Hospital , Soochow University , Chinese Medical Education Association Committee , Beijing Chaoyang Hospital , Capital Medical University ,

Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment

Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment
News provided by
Share this article
SHANGHAI and HONG KONG, April 28, 2021 /PRNewswire/ With the official release and implementation of
the Overall Plan for the Construction of Hainan Free Trade Port, patient can now access global innovative medicines in mainland China. Recently,
the global first-in-class selective inhibitor of nuclear export (SINE) compound, selinexor (XPOVIO®), was prescribed for the first time in mainland China at the Boao Super Hospital in Boao Lecheng Pilot Zone and has been authorized to be expanded beyond the Pilot Zone for the outpatient treatment of relapsed or refractory multiple myeloma (rrMM). Prescribing selinexor for the first time in China is a significant milestone in changing the hematological cancer treatment landscape in the country as ....

Hong Kong , Hongxia Yao , Asia Pacific , Antengene Corporation , Hematological Lymphoma Department , Boao Lecheng International Medical Tourism Pilot Zone , Antengene Corporation Limited , Patient Program , Hainan Chengmei Medicine Co Ltd , National Comprehensive Cancer Network , Named Patient Program , Boao Super Hospital , Diffuse Largeb Cell Lymphoma , Interim Provisions , Imported Drugs , Urgent Need , Hainan Province , Pilot Zone , Hainan Cancer Hospital , Boao Super , Corporation Limited , Asia Pacific Region , Patients Beyond , National Comprehensive Cancer , ஹாங் காங் , ஆசியா பெஸிஃபிக் ,